There is convincing evidence that neurological relapses in multiple sclerosis (MS) are the
clinical counterpart of acute focal inflammation of the central nervous system (CNS) whereas
neurological progression is that of chronic diffuse neurodegeneration. The classical view is
to consider that MS is an organ-specific autoimmune disease, ie that inflammation is the
cause of the neurodegeneration. The succession of relapses eventually leads to
accumulation of disability and clinical progression results from subclinical relapses. A series …